SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

Daniel Acker — Bloomberg via Getty Images

78

Merck

MRK

The pharmaceutical giant raked in $40.1 billion in global sales in 2017, an increase of 1% from the year before. Merck’s superstar cancer immunotherapy drug Keytruda has continued to be the big performer; it alone brought in $1.46 billion in the first quarter of this year–an increase of 150% from the same time period last year. Success has been a mixed blessing, however. Keytruda now plays an outsize role in Merck’s portfolio, responsible for about 15% of the company’s sales. Moreover, plans to expand the drug’s applications have hit a snag: A collaboration with the biotech research firm Incyte to combine the drug with another experimental therapy has been recently halted.

Looking for leads, investment insights, or competitive intelligence?

CEO

Kenneth C. Frazier

CEO Title

Chairman, President & Chief Executive Officer

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

Kenilworth, N.J.

Years on Fortune 500 List

24

Employees

69,000

Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$40,1220.8%
Profits ($M)$2,394.0-38.9%
Assets ($M)$87,872
Total Stockholder Equity ($M)$34,336
Market Value — as of March 29, 2018 ($M)$146,862
Profit Ratios
Profit as % of Revenues6.0%
Profits as % of Assets2.7%
Profits as % of Stockholder Equity7.0%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)0.87
EPS % Change (from 2016)-38.3%
EPS % Change (5 year annual rate)-15.3%
EPS % Change (10 year annual rate)-5.2%
Total Return
Total Return to Investors (2017)-1.5%
Total Return to Investors (5 year, annualized)10.1%
Total Return to Investors (10 year, annualized)3.5%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Merck

Drugmakers Blame Middlemen for High Prices But Still Make Huge Profits

Out of more than 100 business sectors, drug companies are in the top 10 of profits.

Read More →
Fortune's Blue Ribbon Companies 2018

These 56 companies are on at least four of Fortune's 2018 rankings.

Read More →
The 5 Best Biotech and Health Care Stocks to Buy for 2019 Now That Congress Can’t Repeal Obamacare

With Congress split between Republicans and Democrats, pharma and biotech stocks are ready to surge.

Read More →